search
Back to results

Impact of Topical Tranexamic Acid on Pre- and Post-operative Hemoglobin/Hematocrit

Primary Purpose

Fracture of Posterior Wall of Acetabulum

Status
Recruiting
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Tranexamic Acid
Normal saline
Sponsored by
University of Cincinnati
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fracture of Posterior Wall of Acetabulum

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients with an isolated, closed, posterior wall acetabular fracture managed surgically within 7 days of injury. Upper extremity fractures that are non-operative and have no impact on weight-bearing status will be included.
  2. Patients must be skeletally mature.

Exclusion Criteria:

  1. Patients are not skeletally mature.
  2. Patients with any concomitant lower extremity, pelvis, or spine injuries.
  3. Patient admitted as a polytrauma patient to the trauma service due to injury to an internal organ (head, chest, or abdomen).
  4. Patient has an unidentified source of hemorrhage other than acetabular fracture.
  5. Patient requires surgery for treatment of concomitant injuries.
  6. Patient requires multiple surgeries.
  7. Patient has pre-existing thrombus prior to surgery.
  8. Patient with a history of prior pulmonary embolus or other thromboembolic disease.
  9. Patient with a known bleeding disorder.
  10. Patient with a history of renal insufficiency.
  11. Patient who is unable to give consent or is unconscious.

Sites / Locations

  • University of Cincinnati College of MedicineRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Topical TXA Treatment

No Topical Treatment

Arm Description

2 gm TXA/100 ml of normal saline

Normal saline

Outcomes

Primary Outcome Measures

Hemoglobin (Hb)
Hemoglobin (Hb) results
Hematocrit (Hct)
Hematocrit (Hct) results

Secondary Outcome Measures

Full Information

First Posted
July 20, 2021
Last Updated
May 17, 2023
Sponsor
University of Cincinnati
Collaborators
Foundation for Orthopedic Trauma
search

1. Study Identification

Unique Protocol Identification Number
NCT05357079
Brief Title
Impact of Topical Tranexamic Acid on Pre- and Post-operative Hemoglobin/Hematocrit
Official Title
The Impact of Topical Tranexamic Acid on Pre- and Post-operative Hemoglobin / Hematocrit in Isolated Operative Posterior Wall Acetabular Fractures: a Prospective, Randomized, Double-blinded, Multicenter Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 25, 2017 (Actual)
Primary Completion Date
August 30, 2025 (Anticipated)
Study Completion Date
December 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Cincinnati
Collaborators
Foundation for Orthopedic Trauma

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This multi-center, prospective study will evaluate the use of topical tranexamic acid (TXA - Cyklokapron; Pfizer, New York, NY) on pre-operative and post-operative hemoglobin (Hb)/hematocrit (Hct) in patients undergoing operative repair of isolated posterior wall (PW) acetabular fractures.
Detailed Description
In this prospective, randomized, double-blinded, multi-center study comparing topical TXA with placebo, investigators will determine whether topical TXA utilization in isolated PW acetabular surgery has beneficial or detrimental effects. In order to evaluate the delta between pre-operative and post-operative hemoglobin (blood loss parameters) in patients with isolated PW acetabular fractures that were treated with topical TXA or a placebo, investigators will prospectively enroll all eligible patients with the diagnosis of a closed, isolated, PW acetabular fracture that requires surgical fixation. Isolated PW fractures have been chosen to reduce confounding variables, particularly those associated with more complex fracture patterns including longer surgery duration and blood loss. Each subject will have a pre-operative Hb and Hct drawn on the morning of surgery to establish a baseline level. Prior to surgery, subjects will be computer-randomized by pharmacy to one of two groups: a topical TXA group and a control group. The topical TXA group will be treated with 2 gm/100 ml of normal saline, while the control group will be treated with a placebo (normal saline) in a similar fashion to the TXA experimental group. The surgeon and the operative team will be blinded as to whether the patient receives TXA or placebo. Intraoperative transfusion requirements and estimated blood loss (EBL) will be recorded for every patient. Hemoglobin and hematocrit values will be obtained on postoperative day one and two with routine morning blood draws (typically 5 am-9 am). Post-operative transfusion requirements prior to discharge will be recorded. All patients will have standard low molecular weight heparin DVT prophylaxis for four weeks post-operatively. Prospectively demographic data will be collected. Injury and treatment data collected will include date of injury, mechanism of injury, laterality of injury, medical co-morbidities, associated injuries, date of surgery, operative time, estimated operative blood loss (EBL) from both anesthesia and operative surgeon, calculated operative blood loss, as well as hemoglobin/hematocrit as described, and blood transfusions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fracture of Posterior Wall of Acetabulum

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Model Description
A. Specific aims a. To conduct a multi-center study to prospectively evaluate the use of topical tranexamic acid (TXA - Cyklokapron; Pfizer, New York, NY) on pre-operative and post-operative hemoglobin (Hb)/hematocrit (Hct) in patients undergoing operative repair of isolated posterior wall (PW) acetabular fractures.
Masking
Investigator
Allocation
Randomized
Enrollment
98 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Topical TXA Treatment
Arm Type
Experimental
Arm Description
2 gm TXA/100 ml of normal saline
Arm Title
No Topical Treatment
Arm Type
Placebo Comparator
Arm Description
Normal saline
Intervention Type
Drug
Intervention Name(s)
Tranexamic Acid
Other Intervention Name(s)
Cyklokapron, Pfizer
Intervention Description
Topical application
Intervention Type
Drug
Intervention Name(s)
Normal saline
Intervention Description
Topical application
Primary Outcome Measure Information:
Title
Hemoglobin (Hb)
Description
Hemoglobin (Hb) results
Time Frame
Postoperative Day 2
Title
Hematocrit (Hct)
Description
Hematocrit (Hct) results
Time Frame
Postoperative Day 2

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with an isolated, closed, posterior wall acetabular fracture managed surgically within 7 days of injury. Upper extremity fractures that are non-operative and have no impact on weight-bearing status will be included. Patients must be skeletally mature. Exclusion Criteria: Patients are not skeletally mature. Patients with any concomitant lower extremity, pelvis, or spine injuries. Patient admitted as a polytrauma patient to the trauma service due to injury to an internal organ (head, chest, or abdomen). Patient has an unidentified source of hemorrhage other than acetabular fracture. Patient requires surgery for treatment of concomitant injuries. Patient requires multiple surgeries. Patient has pre-existing thrombus prior to surgery. Patient with a history of prior pulmonary embolus or other thromboembolic disease. Patient with a known bleeding disorder. Patient with a history of renal insufficiency. Patient who is unable to give consent or is unconscious.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michael Archdeacon, MD
Phone
513-558-6077
Email
shelley.hess@uc.edu
Facility Information:
Facility Name
University of Cincinnati College of Medicine
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45267
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kim Hasselfeld
Phone
513-777-6213
Email
hasselky@uc.edu
First Name & Middle Initial & Last Name & Degree
Shelly Hess
Email
shelley.hess@uc.edu

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
17921834
Citation
Magnussen RA, Tressler MA, Obremskey WT, Kregor PJ. Predicting blood loss in isolated pelvic and acetabular high-energy trauma. J Orthop Trauma. 2007 Oct;21(9):603-7. doi: 10.1097/BOT.0b013e3181599c27.
Results Reference
background
PubMed Identifier
18757950
Citation
Lemaire R. Strategies for blood management in orthopaedic and trauma surgery. J Bone Joint Surg Br. 2008 Sep;90(9):1128-36. doi: 10.1302/0301-620X.90B9.21115.
Results Reference
background
PubMed Identifier
9085968
Citation
Hiippala ST, Strid LJ, Wennerstrand MI, Arvela JV, Niemela HM, Mantyla SK, Kuisma RP, Ylinen JE. Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. Anesth Analg. 1997 Apr;84(4):839-44. doi: 10.1097/00000539-199704000-00026.
Results Reference
background
PubMed Identifier
15805205
Citation
Yamasaki S, Masuhara K, Fuji T. Tranexamic acid reduces postoperative blood loss in cementless total hip arthroplasty. J Bone Joint Surg Am. 2005 Apr;87(4):766-70. doi: 10.2106/JBJS.D.02046.
Results Reference
background
PubMed Identifier
20063079
Citation
Ralley FE, Berta D, Binns V, Howard J, Naudie DD. One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty. Clin Orthop Relat Res. 2010 Jul;468(7):1905-11. doi: 10.1007/s11999-009-1217-8. Epub 2010 Jan 9. Erratum In: Clin Orthop Relat Res. 2010 May;468(5):1447.
Results Reference
background
PubMed Identifier
16943461
Citation
Phillips SJ, Chavan R, Porter ML, Kay PR, Hodgkinson JP, Purbach B, Reddick AH, Frayne JM. Does salvage and tranexamic acid reduce the need for blood transfusion in revision hip surgery? J Bone Joint Surg Br. 2006 Sep;88(9):1141-2. doi: 10.1302/0301-620X.88B9.17605.
Results Reference
background
PubMed Identifier
16156456
Citation
Johansson T, Pettersson LG, Lisander B. Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients. Acta Orthop. 2005 Jun;76(3):314-9.
Results Reference
background
PubMed Identifier
23521109
Citation
Kelley TC, Tucker KK, Adams MJ, Dalury DF. Use of tranexamic acid results in decreased blood loss and decreased transfusions in patients undergoing staged bilateral total knee arthroplasty. Transfusion. 2014 Jan;54(1):26-30. doi: 10.1111/trf.12167. Epub 2013 Mar 22.
Results Reference
background
PubMed Identifier
26560109
Citation
Piggott RP, Leonard M. Is there a role for antifibrinolytics in pelvic and acetabular fracture surgery? Ir J Med Sci. 2016 Feb;185(1):29-34. doi: 10.1007/s11845-015-1375-5. Epub 2015 Nov 11.
Results Reference
background
PubMed Identifier
14601276
Citation
Ho KM, Ismail H. Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis. Anaesth Intensive Care. 2003 Oct;31(5):529-37. doi: 10.1177/0310057X0303100507.
Results Reference
background
PubMed Identifier
20554319
Citation
CRASH-2 trial collaborators; Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejia-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010 Jul 3;376(9734):23-32. doi: 10.1016/S0140-6736(10)60835-5. Epub 2010 Jun 14.
Results Reference
background
PubMed Identifier
19926634
Citation
Zufferey PJ, Miquet M, Quenet S, Martin P, Adam P, Albaladejo P, Mismetti P, Molliex S; tranexamic acid in hip-fracture surgery (THIF) study. Tranexamic acid in hip fracture surgery: a randomized controlled trial. Br J Anaesth. 2010 Jan;104(1):23-30. doi: 10.1093/bja/aep314.
Results Reference
background
PubMed Identifier
25155138
Citation
Wei W, Wei B. Comparison of topical and intravenous tranexamic acid on blood loss and transfusion rates in total hip arthroplasty. J Arthroplasty. 2014 Nov;29(11):2113-6. doi: 10.1016/j.arth.2014.07.019. Epub 2014 Jul 30.
Results Reference
background
PubMed Identifier
24768543
Citation
Patel JN, Spanyer JM, Smith LS, Huang J, Yakkanti MR, Malkani AL. Comparison of intravenous versus topical tranexamic acid in total knee arthroplasty: a prospective randomized study. J Arthroplasty. 2014 Aug;29(8):1528-31. doi: 10.1016/j.arth.2014.03.011. Epub 2014 Mar 21.
Results Reference
background
PubMed Identifier
24824098
Citation
Dailey SK, Archdeacon MT. Open reduction and internal fixation of acetabulum fractures: does timing of surgery affect blood loss and OR time? J Orthop Trauma. 2014 Sep;28(9):497-501. doi: 10.1097/BOT.0000000000000153.
Results Reference
background
PubMed Identifier
22495528
Citation
Furey AJ, Karp J, O'Toole RV. Does early fixation of posterior wall acetabular fractures lead to increased blood loss? J Orthop Trauma. 2013 Jan;27(1):2-5. doi: 10.1097/BOT.0b013e31824d96de.
Results Reference
background
PubMed Identifier
9689278
Citation
Lisander B, Ivarsson I, Jacobsson SA. Intraoperative autotransfusion is associated with modest reduction of allogeneic transfusion in prosthetic hip surgery. Acta Anaesthesiol Scand. 1998 Jul;42(6):707-12. doi: 10.1111/j.1399-6576.1998.tb05305.x.
Results Reference
background
PubMed Identifier
21936146
Citation
Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962 Feb;51(2):224-32. No abstract available.
Results Reference
background
PubMed Identifier
10068006
Citation
Tornetta P 3rd. Non-operative management of acetabular fractures. The use of dynamic stress views. J Bone Joint Surg Br. 1999 Jan;81(1):67-70. doi: 10.1302/0301-620x.81b1.8805.
Results Reference
background

Learn more about this trial

Impact of Topical Tranexamic Acid on Pre- and Post-operative Hemoglobin/Hematocrit

We'll reach out to this number within 24 hrs